Fig. 3. In vivo tumor responses are mechanism of action–specific and concentration-dependent. In vivo tumor responses are mechanism of action–specific.

Slides:

Advertisements

Similar presentations

Fig. 1. TP is highly expressed in myeloma.

Advertisements

Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fluorescence-based in vivo imaging of MSP.

T2-weighted cross-sectional MR imaging of MSP swarms inside SD rats.

Fig. 2. IL-2/rapamycin–expanded T cells express homing receptors to traffic to lymphoma sites and are resistant to SN-38 toxicity. IL-2/rapamycin–expanded.

CD facilitates RCT in vivo and promotes urinary cholesterol excretion

Fig. 3 CSF1 is expressed in human melanoma.

Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.

Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.

Biocompatibility evaluation in vivo with a mouse subcutaneous implant

Consolidated Standards of Reporting Trials flow diagram of VRC trial

Cell viability tests. Cell viability tests. SEM images of (A) MC3T3-E1 cells and (B) MSCs on days 1, 3, and 5 of culture. (C) Survival rates of MC3T3-E1.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Fig. 2 CFD results. CFD results. Results of CFD simulations in horizontal (left column) and vertical (right column) cross-sections. All models oriented.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 1. MSCs undergo in vivo apoptosis after infusion without affecting immunosuppression. MSCs undergo in vivo apoptosis after infusion without affecting.

T2-weighted cross-sectional MR imaging of MSP swarms inside SD rats.

Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.

Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Fig. 1. In vivo–in vitro validation of [11C]UCB-J as a synaptic density biomarker in the baboon brain. In vivo–in vitro validation of [11C]UCB-J as a synaptic.

Fig. 1. Iontophoretic devices used for the delivery of cytotoxic agents to solid tumors. Iontophoretic devices used for the delivery of cytotoxic agents.

In vivo release of doxycycline hyclate from the GRS in a swine model

Fig. 2. Deficiency of neuronal HS leads to reduced neuroinflammation.

Fig. 2 CD19 CAR T cells expressing tPSMA maintain function in vitro and in vivo. CD19 CAR T cells expressing tPSMA maintain function in vitro and in vivo.

Fig. 2. Bacterial/viral score in COCONUT-conormalized whole-blood validation data sets. Bacterial/viral score in COCONUT-conormalized whole-blood validation.

Colonization in tumor models and different modes of administration

CD mediates metabolism and efflux of crystal-derived cholesterol

HECTD2 knockdown ameliorates Pseudomonas-induced lung injury in vivo

Fig. 2. In vitro activity of DSM265 and its analogs on DHODH and P

Fig. 4 Administration of BMS to mice inhibits autoimmune-relevant pharmacodynamic endpoints driven by IL-12 and IFNα. Administration of BMS

Fig. 3 BMS blocks functional responses in primary immune cells driven by IL-23 and IL-12. BMS blocks functional responses in primary immune.

Fig. 1. DEL-1 is expressed by human and mouse osteoclasts.

Fig. 7 BMS reduces the elevated expression of type I IFN–regulated genes both ex vivo in blood from patients with lupus and in a phase 1 study of.

Fig. 2 In situ vaccination of CpG in combination with anti-OX40 antibody cures established local and distant tumors. In situ vaccination of CpG in combination.

BMS blocks functional responses in primary immune cells driven by IFNα

Fig. 1. Detection of circulating tumor DNA in CRPC patients.

Fig. 5 Treatment with BMS (PO BID) protects from wasting and colitis in two SCID mouse models. Treatment with BMS (PO BID) protects from.

Fig. 3 2D horizontal Br−tracer and cable bacteria distributions.

The microchip-based drug delivery device and overview of study design

Fig. 7. CIVO performance in canine lymphoma tumors demonstrates spatially restricted responses linked to drug mechanism. CIVO performance in canine lymphoma.

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Fig. 6. Prolonged miR overexpression in the adult heart reduces fibrotic scar size but compromises cardiac function after MI. Prolonged miR

Fig. 2 PK dosing results. PK dosing results. (A) Plasma concentration of hPTH(1–34) versus time after release of 40-μg dose from implanted microchip device.

Fig. 3 Local Maraba treatment of TNBC tumors provides long-term systemic protection. Local Maraba treatment of TNBC tumors provides long-term systemic.

Fig. 1 Structure and absorption spectra of the P

Fig. 4 Dox-CBD-SA treatment shows reduced toxicity.

Fig. 3. Human liver tissue seed graft function.

Candesartan diminishes SynO-mediated morphofunctional responses in microglia. Candesartan diminishes SynO-mediated morphofunctional responses in microglia.

Fig. 6. Confocal image series at 10-μm intervals through the full retinal thickness at P48 in WT and vldlr-null mice. Confocal image series at 10-μm intervals.

Fig. 6 Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9 in vivo. Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9.

Fig. 2 In vitro and preclinical study with 18F-MPG.

Delineating cancer evolution with single-cell sequencing

Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

Fig. 2 Increasing KLF17, CDH1, and LASS2 expression reduced malignant progression and promoted apoptosis of tumor cells. Increasing KLF17, CDH1, and LASS2.

Fig. 7 BEL immune response.

Fig. 3. miR overexpression leads to increased cell proliferation as well as altered differentiation and metabolism in cardiomyocytes. miR

Fig. 3 Superiority of BAFF-R versus CD19-CAR T cells in a Burkitt lymphoma model is not due to greater tumor antigen density. Superiority of BAFF-R versus.

Fig. 4 In vivo siRIPK4 delivered by HNTs inhibits tumor promotion of T24 bladder cancer cells in an in situ model of bladder cancer (n = 12 rats in each.

Fig. 3 Supraballs and films assembled from binary 219/217nm SPs/SMPs.

Fig. 3. Association between peak CTL019 expansion and response.

CD36 expression in tissue adjacent and distal to the tumor.

Fig. 3. Col IV–Ac2-26 NPs suppress lesional superoxide and increase lesional Il10 mRNA in Ldlr−/− mice with established atherosclerosis. Col IV–Ac2-26.

Fig. 5 The complex of antibody and dye can afford to target imaging in the NIR-II window. The complex of antibody and dye can afford to target imaging.

Fig. 1. Schematic description of whole-exome or targeted next-generation sequencing analyses. Schematic description of whole-exome or targeted next-generation.

Fig. 3 Postnatal assembly of the humanized gut microbiota.

In vivo function of MeTro sealants using rat incision model of lungs

Fig. 3. Effects of SFN in mice with diet-induced diabetes.

Fig. 4 Rotavirus induces the type I IFN pathway and release of ATP by tumor cells. Rotavirus induces the type I IFN pathway and release of ATP by tumor.

Fig. 2. Ex vivo and in vivo investigation of the mechanism of drug delivery enhancement with ultrasound. Ex vivo and in vivo investigation of the mechanism.

Presentation transcript:

Fig. 3. In vivo tumor responses are mechanism of action–specific and concentration-dependent. In vivo tumor responses are mechanism of action–specific and concentration-dependent. (A and B) Ramos lymphoma tumors were injected with arrays containing a vehicle control, mafosfamide (MAF), doxorubicin (DOX), vincristine, and prednisolone (PRED), each delivered from a distinct needle within the array, and tumors were resected 24 hours later. Tissue sections from multiple depths along the injection column were stained with H&E or antibodies recognizing γH2AX, pHH3, or CC3. (A) Representative whole-section images from resected tumors. (B) Individual injection sites from tumors. (C) Ramos lymphoma tumors were microinjected with varying concentrations of each drug, each concentration through a distinct needle within the array, and tumors resected 24 and 72 hours after microinjection. Tissue sections were stained with antibodies recognizing γH2AX, pHH3, or CC3, and the fraction of biomarker-positive cells was plotted as a function of radial distance from the injection site. Data are average responses across multiple tumors ± SEM (mafosfamide, n = 5; doxorubicin, n = 15; vincristine, n = 8; and prednisolone, n = 4). Richard A. Klinghoffer et al., Sci Transl Med 2015;7:284ra58 Copyright © 2015, American Association for the Advancement of Science